Psychedelic Therapy for Depression
Saanvi Gutta
Zenodo (CERN European Organization for Nuclear Research) August 11, 2026 preprint DOI: 10.5281/zenodo.21893915 (opens in new tab)
Study at a glance
AI-extracted from the abstract| Characteristics | Mixed-methods study |
|---|---|
| Topics | Depression Psychedelic-assisted therapy |
| Key points | Argues that regulatory, clinical, and infrastructural barriers currently prevent psychedelic therapy from entering mainstream hospital care, and proposes a practical roadmap for safe, ethical, and scalable implementation. |
Abstract
Depression affects over 280 million people worldwide and remains one of the leading causes of disability and suicide. Existing treatments such as SSRIs and traditional psychotherapy often fail to provide relief, especially for individuals with treatment‑resistant depression. Recent clinical trials suggest that psychedelic‑assisted therapy using psilocybin or MDMA may offer rapid and durable improvements in depressive symptoms. However, despite promising evidence, these treatments remain confined to research settings. This paper examines the regulatory, clinical, and infrastructural barriers preventing psychedelic therapy from entering mainstream hospital care. Through a mixed‑methods approach - including literature review, case studies, expert interviews, and systems mapping - this research outlines the requirements for safe, ethical, and scalable implementation. The goal is to provide a practical roadmap for hospitals, policymakers, and clinicians seeking to translate psychedelic research into accessible mental health treatment.
Comparable studies
Other qualitative studies on psychedelic-assisted therapy, most cited first.
| Study | Year | Design | Participants |
|---|---|---|---|
| Patients’ Accounts of Increased “Connectedness” and “Acceptance” After Psilocybin for Treatment-Resistant Depression Patients with treatment-resistant depression enrolled in an open-label trial of psilocybin | 2017 | Qualitative study | n = 20 |
| LSD-assisted psychotherapy for anxiety associated with a life-threatening disease: A qualitative study of acute and sustained subjective effects Patients with anxiety associated with life-threatening diseases | 2014 | Prospective follow-up with qualitative content analysis | n = 10 |
| Patient Experiences of Psilocybin-Assisted Psychotherapy: An Interpretative Phenomenological Analysis Adults aged 22 to 69 with clinically elevated anxiety associated with a cancer diagnosis | 2017 | Qualitative study | n = 13 |
| Psychedelic therapy for smoking cessation: Qualitative analysis of participant accounts Participants who completed a psilocybin-facilitated smoking cessation pilot study | 2018 | Qualitative follow-up study using semi-structured interviews and thematic analysis | n = 12 |
| The hidden therapist: evidence for a central role of music in psychedelic therapy Patients undergoing psychedelic therapy with psilocybin for treatment-resistant depression | 2018 | Qualitative study | n = 19 |